Palavras-chave
Como Citar
Resumo
Este artigo tem por objetivo realizar uma revisão sistemática e meta-análise para comparar a eficácia e segurança do ácido bempedoico às estatinas no tratamento da dislipidemia. A metodologia seguiu as diretrizes PRISMA, utilizando as bases PubMed, Embase, Cochrane Library e Scopus, com os termos “bempedoic acid”, “statins”, “cardiovascular events”, “mortality” e “adverse events”. Foram incluídos ensaios clínicos randomizados até 1º de janeiro de 2025. Os resultados evidenciaram que o ácido bempedoico não apresentou superioridade às estatinas na redução de eventos cardiovasculares e mortalidade, embora tenha demonstrado menor ocorrência de eventos adversos. Conclui-se que o ácido bempedoico é uma alternativa viável para pacientes intolerantes às estatinas, mas estudos futuros são necessários para elucidar seu impacto na redução do risco cardiovascular.
Referências
DI MINNO, Alessandro; LUPOLI, Roberta; CALCATERRA, Ilaria; et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: systematic review and meta-analysis of randomized controlled trials. Journal of the American Heart Association, v. 9, n. 12, p. e016262, 2020. Disponível em: REVISTAS AHA. Acesso em: 22 jan. 2025.
MUTSCHLECHNER, David; TSCHARRE, Manuela; HUBER, Kurt; GREMMEL, Thomas. Cardiovascular events in patients treated with bempedoic acid vs. placebo: systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, v. 9, n. 6, p. 583–591, 2023.
KRISHNA MOHAN, G. V.; CHENNA, V. S. H.; TIRUMANDYAM, G.; et al. Efficacy and safety of bempedoic acid to prevent cardiovascular events in individuals at risk of cardiovascular diseases: a meta-analysis of randomized-control trials. Cureus, v. 15, n. 5, p. e38662, 2023.
BALLANTYNE, Christie M.; BANACH, Maciej; CATAPANO, Alberico L.; et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. Journal of the American College of Cardiology, v. 78, n. 2, p. 115–129, 2021.
GITTOES, Neil J. L.; SCHEEN, André J.; PETERSEN, John; et al. A randomized, double-blind, placebo-controlled, phase 3 trial of bempedoic acid in patients with hypercholesterolemia and statin intolerance. European Journal of Preventive Cardiology, v. 28, n. 10, p. 1052–1060, 2021.
THOMPSON, Paul D.; RUBINO, John; STERLING, Lulu R.; et al. Bempedoic acid in patients with statin intolerance: pooled analysis of phase 3 trials. Journal of Clinical Lipidology, v. 14, n. 5, p. 678–687, 2020.
GINSBERG, Henry N.; RITCHIE, Mary; GUPTA, Anuradha; et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis, v. 277, p. 195–203, 2018.
BALLANTYNE, Christie M.; DAVIDSON, Michael H.; MACDOUGALL, Diane E.; et al. Efficacy and safety of bempedoic acid added to maximally tolerated statins in patients with hypercholesterolemia: a randomized, placebo-controlled study. Atherosclerosis, v. 277, p. 195–203, 2018.
RAY, Kausik K.; LANDMESSER, Ulf; LEITER, Lawrence A.; et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. New England Journal of Medicine, v. 376, p. 1430–1440, 2017.
CANNON, Christopher P.; BLAZING, Michael A.; GIUGLIANO, Robert P.; et al. Ezetimibe added to statin therapy after acute coronary syndromes. New England Journal of Medicine, v. 372, p. 2387–2397, 2015.
SABATINE, Marc S.; GIUGLIANO, Robert P.; KEECH, Anthony C.; et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. New England Journal of Medicine, v. 376, p. 1713–1722, 2017.
SCHWARTZ, Gerald G.; STEG, Philippe G.; SZAREK, Michael; et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. New England Journal of Medicine, v. 379, p. 2097–2107, 2018.
FERGUSON, John F.; BERGLUND, Lars; CARR, John J.; et al. Genetic variation in the β2-adrenergic receptor is associated with carotid intima-media thickness in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, v. 233, n. 2, p. 661–668, 2014.
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Matheus Jannuzzi Moreira de Mendonça, Vitor Aliot da Costa, Vitor Hugo Becchi Rubio, Paulo Rogério Borges Rosmaninho Varandas, Ana Carolina Furio da Cunha, Valter Zumpano Filho, Higor Rafael de Figueiredo Oliveira